Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Drug Safety

Patient Rights Patient Risks Semaglutide DCCR

Soleno Faces Securities Class Action Over DCCR Safety as Investors Weigh May 5 Lead‑Plaintiff Deadline

Investors now confront a court test of claims that Soleno hid safety risks tied to its Prader‑Willi drug and overstated its launch outlook.

Soleno Hit With Securities Class Action Over Prader‑Willi Drug DCCR

Soleno Therapeutics Sued in Federal Securities Class Action Over DCCR Safety Disclosures